(Reuters) – Eli Lilly (NYSE:) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday.
The company has received the Hong Kong government approval to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
The impending “super El Niño” will send global temperatures rising, but is also expected to…
Ontario Premier Doug Ford says “no one is more ticked off” than him about the…
The outcome and duration of the Middle East conflict remain uncertain. What is clear is…
Around 300 people were stranded mid-air after a technical malfunction halted the Gulmarg Gondola system…
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure The entire…
Ontario Premier Doug Ford’s government is going to court to try to prevent the release…